<DOC>
	<DOCNO>NCT02044601</DOCNO>
	<brief_summary>The goal Phase I part clinical research study find high tolerable dose onartuzumab give erlotinib standard chemoradiation ( paclitaxel carboplatin ) patient NSCLC . The goal Phase II learn onartuzumab plus erlotinib chemoradiation help control NSCLC . The safety drug also study .</brief_summary>
	<brief_title>Biomarker-Integrated Approach Targeted Therapy Lung Cancer Elimination Plus External Beam Radiation Therapy ( BATTLE-XRT )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study EGFR mutation , enrol Arm A . If wild-type EGFR , randomly assign ( flip coin ) either Arm B C. You equal chance enrol either arm . - If Arm A , receive standard chemoradiation , erlotinib , onartuzumab . - If Arm B , receive standard chemoradiation , erlotinib , onartuzumab . - If Arm C , receive standard chemoradiation onartuzumab . If assign Arm A B , receive standard chemoradiation , erlotinib , onartuzumab . You assign dose level onartuzumab base join study . After first dose level onartuzumab give , watch 2 week end radiation treatment check serious side effect dose level . If participant first group intolerable side effect , low dose combination study drug may test . Once high tolerable dose find , extra participant receive onartuzumab dose level . All participant Arms A B receive dose level erlotinib . Study Drug Administration : All participant receive onartuzumab vein Day 1 3-week cycle . The first infusion give 60 minute . If infusion tolerate , dose give 30 minute . You receive paclitaxel carboplatin vein 6 hour 1 time week 7 week . You receive separate consent form chemoradiation , describe procedure risk detail . If take erlotinib , take mouth 1 cup water . You take erlotinib time every day , least 1 hour meal least 2 hour meal . Study Visits : One ( 1 ) time week : - You physical exam . - Blood ( 2 teaspoon ) draw routine test . If take Coumadin similar drug , blood also use check well blood clot . Length Study : You may continue take onartuzumab complete radiation therapy . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study 4 year last dose study drug . Follow-Up : You follow-up visit around 30 day last dose study drug , every 3 month 2 year , every 4 month next 2 year . During visit : - You physical exam . - You CT PET scan check status disease . - If take Coumadin similar drug , blood ( 2 teaspoon ) drawn check well blood clot . You call every 4 week ask long doctor think need . This investigational study . Onartuzumab FDA approve commercially available . It currently use research purpose . Erlotinib , carboplatin , paclitaxel FDA approve commercially available treatment NSCLC , use study investigational . Radiation therapy deliver use FDA-approved commercially available method . The study doctor explain study drug design work . Up 90 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically cytologically document NSCLC , include squamous cell carcinoma , adenocarcinoma ( include bronchoalveolar cell ) , large cell anaplastic carcinoma ( include giant clear cell carcinoma ) poorly differentiate ( otherwise specify , NOS ) nonsmall cell lung cancer ; totally resect tumor exclude . Patients tumor tissue biomarker test available . Archival sample may use . Patients without tissue biomarker test may enrol discretion investigator . The determination MET status do pathologist train use SP44 antibody Ventana platform use Ventana/Genentech algorithm . 2 . Patients T1or T2 disease N2 T3N12 disease ( Stage IIIA ) eligible deem inoperable . Patients T4 N T N2 N3 disease eligible unresectable . Patients may limited stage M1 disease , maximum 3 metastatic site ( include single brain mets ) site treat definitive intent , unless longer clinically present secondary induction chemotherapy . Treatment sit deliver prior trial . Measurable disease require . See Response Evaluation Criteria Solid Tumors ( RECIST ) definition measurable disease . 3 . Patients must &gt; /=18 year age . 4 . Patients Zubrod performance status 02 . 5 . Adequate hematologic function define : ANC &gt; /= 1,500/mm3 , platelet &gt; /= 100,000/mm3 , hemoglobin &gt; /= 9 g/dL ( prior transfusion ) ; adequate hepatic function define : total bilirubin &lt; /= 1.5 mg/dl , SGOT SGPT &lt; /= 3 x ULN , adequate renal function define serum creatinine level &lt; /= 2.0 mg/dl , alkaline phosphatase &lt; /= 2.5 x ULN , glucose &lt; /= 2 x ULN . 6 . FEV1 &gt; /= 1000 cc . 7 . Patients pleural effusion transudate , cytologically negative nonbloody eligible radiation oncologist feel tumor still encompass within reasonable field radiotherapy . If pleural effusion see chest compute tomography ( CT ) chest xray ( CXR ) small tap , patient eligible . 8 . If patient exploratory thoracotomy , must recover procedure ( &lt; /= grade 1 baseline ) . Exploratory Thoracotomy begin treatment within one month . 9 . Women childbearing potential ( A woman childbearing potential sexually mature woman undergone hysterectomy naturally postmenopausal least 24 consecutive month [ i.e. , menses time precede 24 consecutive month ] ) male participant must practice effective contraception ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) throughout study four week completion treatment . 10 . For woman childbearing potential , urine blood pregnancy test must perform within 48 hour prior start protocol treatment . 11 . Prior induction chemotherapy allow , prior target therapy . Patients progression EGFR target agent also allow , stratify two arm . 12 . Patients must sign studyspecific consent form prior study entry . 1 . Active pulmonary infection responsive conventional antibiotic 2 . History interstitial lung disease . 3 . History severe chronic obstructive pulmonary disease ( COPD ) require &gt; /= 3 hospitalization past year . 4 . Significant history cardiac disease , i.e. , uncontrolled hypertension ( i.e . ca n't reduce blood pressure ( BP ) systolic 160 diastolic 100 ) , unstable angina , uncompensated congestive heart failure , myocardial infarction within past 2 month , cardiac ventricular arrhythmia require medication . 5 . Patients &gt; grade 3 neuropathy . 6 . Evidence life threaten disease result life expectancy le 3 month . 7 . Women pregnant breast feeding , treatment involve unforeseeable risk participant , embryo , fetus , nurse infant ; woman positive pregnancy test enrollment prior study drug administration . 8 . Women childbearing potential male participant unwilling unable use acceptable method contraception ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) throughout study four week completion treatment use prohibit contraceptive method ( method unknown efficacy ) . 9 . Patients currently participate clinical trial and/or participate clinical trial ( These patient may enrol radiation must start within 15 day previous experiment therapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Lung Cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Squamous cell carcinoma lung</keyword>
	<keyword>Adenocarcinoma lung</keyword>
	<keyword>Radiation therapy</keyword>
	<keyword>Proton therapy</keyword>
	<keyword>XRT</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Onartuzumab</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Erlotinib hydrochloride</keyword>
	<keyword>OSI-774</keyword>
	<keyword>CP358774</keyword>
	<keyword>Tarceva</keyword>
</DOC>